Page last updated: 2024-12-08
gvs 111
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 180496 |
| CHEMBL ID | 4303687 |
| SCHEMBL ID | 194807 |
| MeSH ID | M0271473 |
Synonyms (38)
| Synonym |
|---|
| glycine, n-(1-(phenylacetyl)-l-prolyl)-, ethyl ester |
| noopept , |
| glycine, 1-(phenylacetyl)-l-prolyl-, ethyl ester |
| ethyl phenylacetyl-pro-gly |
| gvs 111 |
| gvs-111 |
| ethyl 2-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate |
| n-phenylacetyl-l-prolylglycine ethyl ester |
| 157115-85-0 |
| unii-4qbj98683m |
| n-(1-(phenylacetyl)-l-prolyl)glycine ethyl ester |
| AKOS016012268 |
| 4qbj98683m , |
| AM84514 |
| HY-17456 |
| CS-1575 |
| SCHEMBL194807 |
| omberacetam [who-dd] |
| omberacetam [inn] |
| j759.455k , |
| omberacetam |
| (s)-ethyl 2-(1-(2-phenylacetyl)pyrrolidine-2-carboxamido)acetate |
| DTXSID80166214 |
| ethyl 1-(phenylacetyl)-l-prolylglycinate |
| noopept, >=98% (hplc) |
| NCGC00378939-05 |
| ethyl (2-phenylacetyl)-l-prolylglycinate |
| AS-10555 |
| n-[1-(phenylacetyl)-l-prolyl]glycine ethyl ester |
| ethyl n-[1-(phenylacetyl)-l-prolyl]glycinate |
| N1120 |
| Q7049784 |
| ethyl 2-{[(2s)-1-(2-phenylacetyl)pyrrolidin-2-yl]formamido}acetate |
| dvd-111 |
| sgs-111 |
| CHEMBL4303687 |
| glycine, 1-(2-phenylacetyl)-l-prolyl-, ethyl ester |
| C72975 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "The study evaluated clinical efficiency of noopept used to prevent adverse side effects of antituberculous agents." | ( [Prevention of neuro- and cardiotoxic side effects of tuberculosis chemotherapy with noopept]. Gol'dzon, MA; Khlebova, NV; Kondria, AV; Lysov, AV; Mordyk, AV, 2009) | 0.35 |
| " Noopept does not bind to a sterically specific site in the α-Syn molecule as revealed by heteronuclear two-dimensional NMR analysis, but due to hydrophobic interactions with toxic amyloid oligomers, it prompts their rapid sequestration into larger fibrillar amyloid aggregates." | ( Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. Gharibyan, AL; Jia, X; Liu, Y; Morozova-Roche, LA; Öhman, A; Olofsson, A, 2011) | 0.37 |
| "Neuropathic pain and oxidative neurotoxicity are two adverse main actions of diabetes mellitus (DM)." | ( Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats. Akatlı, AN; Çiğ, B; Düzova, H; Gürbüz, P; Nazıroğlu, M, 2021) | 0.62 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The development of nootropic drugs based on natural neuropeptides with high pharmacological activity and improved pharmacokinetic properties (enzymatic stability, high bioavailability, and good permeability through the BBB) is an important problem of modern neuropsychopharmacology." | ( [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]. Boyko, SS; Shevchenko, RV; Zherdev, VP, 2018) | 0.48 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "It is shown that the two-week use of self-massage of the head and neck in combination with the pharmacological drug Noopept improves the functional state and increases the professional performance of elderly teachers compared to single use of nootropic drug." | ( [The influence of self-massage combined with drug Noopept on the professional performance of teachers older.] Buinov, LG; Lysenko, AV; Lysenko, DS; Sorokina, LA, ) | 0.13 |
Bioavailability
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "35 ml) were added single dosing into this chamber with living physiological solution in concentration 10(-15)-10(-27) mol/l." | ( [Regulation of the neuronal functional state by ultra low doses of different biologically active substances. Nonspecific effect ]. Grechenko, TN; Terekhova, SF, ) | 0.13 |
| "We studied the effects of new nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) in various dosage regimens on the dynamics of glycemia, body weight, and pain sensitivity in rats receiving diabetogenic toxin streptozotocin." | ( Efficiency of noopept in streptozotocin-induced diabetes in rats. Gudascheva, TA; Ivanova, EA; Kapitsa, IG; Ostrovskaya, RU; Ozerova, IV; Seredenin, SB; Voronina, TA, 2013) | 0.39 |
| " Results were found fairly encouraging and created a scope of reducing both dose and dosing frequency to eventually improve the associated patient compliance." | ( QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated Noopept: Exploring a patient friendly, once-daily option to manage dementia. Srivastava, PK; Thakkar, HP, 2021) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| G | Vesicular stomatitis virus | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 37.9083 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 37.9083 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (45)
Molecular Functions (18)
Ceullar Components (22)
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (68)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.82) | 18.2507 |
| 2000's | 27 (39.71) | 29.6817 |
| 2010's | 27 (39.71) | 24.3611 |
| 2020's | 8 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (2.20%) | 5.53% |
| Reviews | 2 (2.20%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 87 (95.60%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||